Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
3.325
-0.045 (-1.34%)
Apr 29, 2026, 11:54 AM EDT - Market open
Anavex Life Sciences Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | 2020 - 2016 |
| Cash & Equivalents | 131.75 | 102.58 | 132.19 | 151.02 | 149.16 | 152.11 | Upgrade
|
| Cash & Short-Term Investments | 131.75 | 102.58 | 132.19 | 151.02 | 149.16 | 152.11 | Upgrade
|
| Cash Growth | 9.09% | -22.40% | -12.47% | 1.25% | -1.94% | 420.04% | Upgrade
|
| Other Receivables | 0.84 | 0.81 | 2.45 | 2.71 | 3.19 | 9.14 | Upgrade
|
| Receivables | 0.84 | 0.81 | 2.45 | 2.71 | 3.19 | 9.14 | Upgrade
|
| Prepaid Expenses | 0.4 | 0.43 | 0.93 | 0.65 | 0.35 | 0.37 | Upgrade
|
| Total Current Assets | 132.99 | 103.82 | 135.57 | 154.39 | 152.71 | 161.62 | Upgrade
|
| Total Assets | 132.99 | 103.82 | 135.57 | 154.39 | 152.71 | 161.62 | Upgrade
|
| Accounts Payable | 2.64 | 4.25 | 9.63 | 4.32 | 3.83 | 4.74 | Upgrade
|
| Accrued Expenses | 2.93 | 3.89 | 4.84 | 7.3 | 5.95 | 5.61 | Upgrade
|
| Current Unearned Revenue | 0.81 | 0.81 | 0.84 | 0.92 | 0.44 | 0.44 | Upgrade
|
| Total Current Liabilities | 6.37 | 8.95 | 15.3 | 12.53 | 10.21 | 10.8 | Upgrade
|
| Total Liabilities | 6.37 | 8.95 | 15.3 | 12.53 | 10.21 | 10.8 | Upgrade
|
| Common Stock | 0.09 | 0.09 | 0.09 | 0.08 | 0.08 | 0.08 | Upgrade
|
| Additional Paid-In Capital | 514.65 | 477.23 | 456.25 | 434.84 | 387.98 | 348.33 | Upgrade
|
| Retained Earnings | -388.13 | -382.45 | -336.07 | -293.07 | -245.56 | -197.59 | Upgrade
|
| Shareholders' Equity | 126.62 | 94.87 | 120.26 | 141.85 | 142.49 | 150.82 | Upgrade
|
| Total Liabilities & Equity | 132.99 | 103.82 | 135.57 | 154.39 | 152.71 | 161.62 | Upgrade
|
| Net Cash (Debt) | 131.75 | 102.58 | 132.19 | 151.02 | 149.16 | 152.11 | Upgrade
|
| Net Cash Growth | 9.09% | -22.40% | -12.47% | 1.25% | -1.94% | 420.04% | Upgrade
|
| Net Cash Per Share | 1.53 | 1.20 | 1.58 | 1.89 | 1.94 | 2.18 | Upgrade
|
| Filing Date Shares Outstanding | 92.67 | 89.35 | 84.82 | 82.09 | 77.96 | 76.02 | Upgrade
|
| Total Common Shares Outstanding | 92.67 | 86.67 | 84.8 | 82.07 | 77.94 | 75.92 | Upgrade
|
| Working Capital | 126.62 | 94.87 | 120.26 | 141.85 | 142.49 | 150.82 | Upgrade
|
| Book Value Per Share | 1.37 | 1.09 | 1.42 | 1.73 | 1.83 | 1.99 | Upgrade
|
| Tangible Book Value | 126.62 | 94.87 | 120.26 | 141.85 | 142.49 | 150.82 | Upgrade
|
| Tangible Book Value Per Share | 1.37 | 1.09 | 1.42 | 1.73 | 1.83 | 1.99 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.